ライフサイエンスコーパス: visual analogue scale

1 with an average reduction of nearly 70% on a visual analogue scale).

2 Q-BR45 arm and breast symptoms, and EQ-5D-5L visual analogue scale).

3 otal score and 16.8 [9.4-24.3] for the EQ-5D visual analogue scale).

4 ry outcome was pain, which was assessed by a visual analogue scale.

5 pleasantness (hedonic response) on a 100-mm visual analogue scale.

6 pain 1 week after treatment, according to a visual analogue scale.

7 rated the magnitude of the evoked pain on a visual analogue scale.

8 atients recorded hypoglycaemia symptoms on a visual analogue scale.

9 ar trajectory was found for the EQ (EuroQol) visual analogue scale.

10 d 6.7 (0.5-12.7) points lower on the EuroQol visual analogue scale.

11 CD was only associated with lower EuroQol visual analogue scale.

12 tion, subjective pain was assessed using the visual analogue scale.

13 Pain was evaluated with the visual analogue scale.

14 5-dimension 5-level questionnaire (EQ-5D-5L) visual analogue scale.

15 idence interval -3.8 to -0.5 mm) on a 100 mm visual analogue scale.

16 izing disease activity, measured on a 100-mm visual analogue scale.

17 ) of 36 patients achieved this for the EQ-5D visual analogue scale.

18 Quality of life was assessed by visual analogue scale.

19 pnea and chest tightness were evaluated on a visual analogue scale.

20 ith activity) greater than 13 mm on a 100-mm visual analogue scale.

21 placebo for most FACT-P endpoints and EQ-5D visual analogue scale.

22 en at days 3, 5, 10, and 14 using a 10-point visual analogue scale.

23 d urge) for alcohol, assessed by the Alcohol Visual Analogue Scale.

24 ily symptoms were rated using a 0- to 100-mm visual analogue scale.

25 tion with life scale and the quality of life visual analogue scale.

26 l, 300 kcal) and postprandial symptoms using visual analogue scales.

27 fullness, and hunger were assessed by using visual analogue scales.

28 Rating Scale, Young Mania Rating Scale, and visual analogue scales.

29 surveillance procedures and the device with visual analogue scales.

30 llowed by confidence judgments on continuous visual analogue scales.

31 ts at home on a weekly basis using validated visual analogue scales.

32 Symptoms were evaluated by visual analogue scales.

33 ameters, respiratory gas concentrations, and visual-analogue scales.

34 ty of patient symptoms were assessed using a visual analogue scale (0-100).

35 3 points (95% CI, 8-17) lower on the EuroQol Visual Analogue Scale, 0.15 points (95% CI, 0.12-0.18) l

36 ay of surgery (difference in mean score on a visual-analogue scale, 10.2 mm; 95 percent confidence in

37 x (224 [28%] of 812 vs 99 [16%] of 623), and visual analogue scale (218 [27%] of 803 vs 106 of [18%]

38 on; postprandial symptoms were measured with visual analogue scales 30 minutes after a meal.

39 ence (MID) in pain relief of 1 cm on a 10 cm visual analogue scale: 36% (95% CI 33 to 39)), therapist

40 t PRO measures were the Numeric Rating Scale/Visual Analogue Scale (38 trials), European Organization

41 pain (mean difference (MD) on 100-millimeter visual analogue scale = -7.7 mm; 95% CI -13.92 to -1.43;

42 ted mean difference (WMD) 0.28 cm on a 10 cm visual analogue scale (95% CI -1.18 to 1.75)), epidural

43 /discomfort and esthetics were assessed with visual analogue scale after 7 days and 6 months, respect

44 Subjective data were collected according to visual analogue scales after 8 weeks of denture-wearing.

45 the EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) visual analogue scale and health utility scores; the pro

46 At 12 months, the visual analogue scale and the other Seattle Angina Quest

47 Individuals graded heel pain with a visual analogue scale and underwent B-mode ultrasonograp

48 tudy showed that quality-of-life data (EQ-5D visual analogue scale and WPA-IS Question 9) are similar

49 ife digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Pati

50 The patient reported pain of 8-10 in VAS (Visual Analogue Scale) and had an ODI (Oswestry Disabili

51 ject recorded pain intensity (using a 100-mm visual-analogue scale) and intake of oral analgesia in a

52 of life (QoL) (EuroQoL-5 Dimensions-5 Levels visual analogue scale), and functional capacity (6 min w

53 r Cough Questionnaire score, change in cough visual analogue scale, and changes in total and subscore

54 , Leicester Cough Questionnaire score, cough visual analogue scale, and SGRQ scores were similar betw

55 The body ache improved by 100% on the visual analogue scale, and the electromyographic dischar

56 on pain were modest (around 1 cm on a 10-cm visual analogue scale, approximating the minimal importa

57 atching of symptom intensity to line length (visual analogue scales), are reviewed for their reliabil

58 improvement were change from baseline in the visual analogue scale area under the curve (VAS AUC) to

59 They completed visual analogue scales assessing the severity of 5 gastr

60 s self-reported leg pain measured by a 0-100 visual analogue scale at 12 months, assuming a non-infer

61 uropean Quality of Life-5 Dimensions-5 Level visual analogue scale at 12 weeks.

62 vels of all volunteers were evaluated by the Visual Analogue Scale at the beginning and the end of th

63 as associated with pain measured through the Visual Analogue Scale (B: - 0.094) and WOMAC (B: 0.062),

64 Measures of appetite were obtained by using visual analogue scales before and after meals.

65 ere asked to rate chest discomfort on 100 mm visual analogue scales before, during, and after drainag

66 igated differences in response patterns on a visual analogue scale between people with frontotemporal

67 The Cytosponge was rated favorably, using a visual analogue scale, compared with endoscopy (p < 0.00

68 ain as assessed by analgesic consumption and visual analogue scales, complications, and length of hos

69 ode Island Change Assessment; and 2) sums of visual analogue scale craving ratings administered durin

70 rage of the 3-d run-in period) on a 0-100 mm visual analogue scale (DeltaVAS), comparing medians usin

71 d the EuroQol-5 dimension-5 level (EQ-5D-5L) visual analogue scale, each collected before treatment a

72 onth and one-year follow-up, and the EuroQOL Visual Analogue Scale (EQ-VAS) and EuroQOL 5-Dimensional

73 ges from baseline between groups in EQ-5D-3L visual analogue scale (EQ-VAS) or utility scores.

74 on 5-Level survey (EQ-5D-5L) and the EuroQol Visual Analogue Scale (EQ-VAS), and cardiac-associated h

75 L 5-Dimensions 5-Levels health questionnaire visual analogue scale [EQ-5D-FL, EQ-VAS], and the Functi

76 y of life (HRQOL)], European Quality of Life Visual Analogue Scale [EQ-VAS; range, 0-100, with higher

77 en dimensions) and 0.79 (between the EuroQol-Visual Analogue Scale [EQ-VAS] and utility score), and a

78 hip between comorbidities and HRQOL (EuroQol Visual Analogue Scale, EQ-5D-3L Index Score, and Kansas

79 measured with the Oswestry Disability Index, visual analogue scale for back pain, health related qual

80 comes such as the Oswestry Disability Index, visual analogue scale for back pain, health related qual

81 Visual Analogue Scale for pain (VAS), fatigue, functiona

82 Visual analogue scale for quality of life (VAS-QoL), VAS

83 ety were measured before and after cues with visual analogue scales for desire to use cocaine now and

84 om criteria and decrease in arm pain using a visual analogue scale from 0 to 100 with a noninferiorit

85 ymptom severity rated a median 7 points on a visual analogue scale from 1 to 10.

86 A Fatigue Visual Analogue Scale (fVAS) was utilized to record fati

87 ife, as measured by the EuroQol 5 Dimensions visual analogue scale, improved by 7.2 points (SD 21.3)

88 change from baseline to week 15 on the EQ-5D visual analogue scale, in contrast to a clinically meani

89 The participants also completed a visual analogue scale instrument on level of discomfort

90 pain-free by an Izbicki Pain Score <=10 and visual analogue scale <=4.

91 .84; mean difference, 0.05, P = .06; EuroQol Visual Analogue Scale: mean, 1.83 vs 1.81, mean differen

92 nolence (via Karolinska Sleepiness Scale and Visual Analogue Scale measures) and sleep (via polysomno

93 We compared pain perception (100 mm visual analogue scale), muscle sympathetic nerve activit

94 th DED completed the eye dryness score (EDS) visual analogue scale, Ocular Comfort Index (OCI), and W

95 de also significantly improved scores on the visual analogue scale of cough (mean difference vs. plac

96 Secondary end points were visual analogue scale of cough and the St. George's Resp

97 aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; a

98 ether the frequency and severity (based on a visual analogue scale) of 12 particular symptoms in pati

99 e Seattle Angina Questionnaire and a generic visual analogue scale on health status.

100 area under the curve (AUC) of the score on a visual-analogue scale over the course of 72 hours, and t

101 groups for change from baseline in EQ-5D-5L visual analogue scale (p=0.060).

102 ad better peak-season rhinitis scores on the visual-analogue scale (P=0.006), peak-season daily nasal

103 ual analog scale score (Euro Quality of Life Visual Analogue Scale; P = .0025), were also demonstrate

104 seen in patients experiencing pain, with the Visual Analogue Scale pain score reducing by 64% (P < 0.

105 ting Scale (r = -0.4965, P < 0.01), Rhinitis Visual Analogue Scale (r = 0.5722, P < 0.01) and asthma

106 e was subjective pain as measured by a 10-cm visual analogue scale ranging from 0 (no pain) to 10 (wo

107 bjective snoring severity (SS, measured on a visual analogue scale ranging from 0 to 10) and the obje

108 he Physician's Global Assessment score (on a visual-analogue scale ranging from 0 [no disease activit

109 rted dyspnea (treatment difference, 0.7 on a visual-analogue scale ranging from 1 to 10; 95% confiden

110 y outcome was the intensity of leg pain on a visual analogue scale (ranging from 0 to 10, with higher

111 in Scale-Revised) and anxiety (measured by a visual analogue scale) reported by the patient, caregive

112 agnitude of thermal and wetness perceptions (visual analogue scale) resulting from the application of

113 Rhinitis severity was assessed using a visual analogue scale; rhinitis was classified according

114 The median Euro-Quality of Life-Visual Analogue Scale score at 6 months was 70 (55-80) a

115 PTED had a statistically significantly lower visual analogue scale score for leg pain (median 7.0, in

116 ), a statistically significant difference in visual analogue scale score in favor of acupuncture (6.3

117 were also required to have a cough severity visual analogue scale score of 40 mm or more at screenin

118 Outcome measures included pain (visual analogue scale score), functional assessment (Con

119 The mean nausea score on the Visual Analogue Scale (score 0-10) was greater during th

120 ous deferred lesions had significantly lower visual analogue scale scores (78.7 14.2 versus 86.8 14.7

121 act of demographic factors and NSAID type on visual analogue scale scores was statistically analysed.

122 EuroQol-visual analogue scale scores were lower for frail compar

123 TC QLQ-C30 global health status and EQ-5D-5L visual analogue scale scores were observed in post-conso

124 n wound dressing, assessed with the use of a visual analogue scale (scores range from 0 to 10, with h

125 Hospital Anxiety and Depression Scale, EQ-5D visual analogue scale, sociodemographics, suicidal ideat

126 LQ-BR45 arm symptoms scale, and the EQ-5D-5L visual analogue scale) suggested T-DXd was numerically f

127 h, and 24 h vs 14 of 61 [23%]; p=0.044) and visual analogue scale through day 14 (8214 mm x h [SD 87

128 Isowork dyspnea decreased as assessed with a visual analogue scale (VAS) (79.6 +/- 5.2 versus 49.3 +/

129 iate neuropathic pain relief was assessed by visual analogue scale (VAS) after connecting the electro

130 The satisfaction visual analogue scale (VAS) after using the medical devi

131 Nasal visual analogue scale (VAS) and blockage scores were wor

132 performed for patient-reported pain using a visual analogue scale (VAS) and for function using the q

133 Symptoms were assessed by a visual analogue scale (VAS) and symptom specific quality

134 sessed with the three-level EQ-5D (EQ-5D-3L) visual analogue scale (VAS) and UK utility index.

135 Main outcome measures were visual analogue scale (VAS) assessments for "pain," "num

136 Patient comfort was evaluated using a visual analogue scale (VAS) at 12 months.

137 LQ-MY20), EQ 5 dimensions (EQ-5D), and EQ-5D visual analogue scale (VAS) at baseline and follow-up ti

138 nificantly improved median score on a 100 mm visual analogue scale (VAS) by 5 mm (range -2 to 14; p=0

139 included the Neck Disability Index (NDI) and Visual Analogue Scale (VAS) for neck and arm pain.

140 re assessed with the Tsui torticollis scale, Visual Analogue Scale (VAS) for pain and Fugl-Meyer scal

141 ASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a releva

142 described their subjective condition with a visual analogue scale (VAS) from 0 to 10 (0 = normal; 10

143 days and breathlessness measured on a 100 mm visual analogue scale (VAS) in the 2 h after initiation

144 Visual Analogue Scale (VAS) is a validated tool to asses

145 The Visual Analogue Scale (VAS) is an existing tool to measu

146 Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume.

147 14, and 30 days, self-reported pain using a visual analogue scale (VAS) recorded on the 0 to 100 sca

148 tores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall aller

149 Weekly visual analogue scale (VAS) scores for myalgia and speci

150 ol items according to EPOS control criteria, visual analogue scale (VAS) scores for total and individ

151 rs") comprising the UCEIS were scored with a visual analogue scale (VAS) to assess overall severity.

152 Additionally, the visual analogue scale (VAS) was evaluated to assess subj

153 (Thai version) descriptive system and the EQ visual analogue scale (VAS) was instrument for QoL evalu

154 thy (VISA-A), the EQ5D questionnaire and the visual analogue scale (VAS) were used for evaluation.

155 Validated questionnaires and a visual analogue scale (VAS) were used for the assessment

156 ubjects (total n=28) rated pleasantness on a visual analogue scale (VAS) when we stroked with a soft

157 naire (DEQ-5), rating of eye dryness using a visual analogue scale (VAS), and noninvasive tear film b

158 mb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS), body mass index (calculated

159 as assessed using the ASES Total score, pain visual analogue scale (VAS), RAND Short Form-36 Health S

160 ensitivity C-reactive protein (hs-CRP) and a visual analogue scale (VAS), respectively.

161 n nasal polyp score (NPS), nasal obstruction visual analogue scale (VAS), Sino-nasal Outcome Test-22

162 Discomfort scores were also assessed with a visual analogue scale (VAS).

163 before and after PV was measured by using a visual analogue scale (VAS).

164 y scored the pain intensity on an electronic visual analogue scale (VAS).

165 1.4 (95% CI -1.9 to 4.7) points for EQ-5D-5L visual analogue scale (VAS).

166 .96 (0.85) versus -6.64 (0.94) for the EQ-5D visual analogue scale (VAS).

167 The pain was evaluated with Visual Analogue Scale (VAS).

168 severity of the pain was evaluated with the visual analogue scale (VAS).

169 was assessed with EuroQol questionnaire and visual analogue scale (VAS).

170 ectional study) and (iii) to follow-up using visual analogue scale (VAS).

171 ctivity of uncontrolled rhinitis assessed by visual analogue scale (VAS).

172 those seen with the wild-type Elstar using a visual analogue scale (VAS).

173 as evaluated by both ARIA severity items and visual analogue scale (VAS).

174 ointestinal symptoms' remission evaluated by Visual Analogue Scale (VAS); secondary endpoint was the

175 index (scores range from -0.1 to 0.95) and a visual analogue scale (VAS; scores range from 0 to 100);

176 the EHP30 Quality-of-Life Questionnaire and visual analogue scales (VAS) for dysmenorrhea, chronic p

177 ire (HAQ), Short Form Health Survey (SF-36), Visual Analogue Scales (VAS) for gastrointestinal compla

178 nd Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic sympto

179 as determined by reported symptoms and using visual analogue scales (VAS) for pain, tingling and disc

180 arison measures, participants completed four Visual Analogue Scales (VAS) to assess musical sound qua

181 Visual analogue scales (VAS) were used for pain assessme

182 rasound gastric antrum measurements, satiety visual analogue scales (VAS), and blood samples for anal

183 reported a 20.1% improvement (P < 0.001) in Visual Analogue Scales (VAS), reflecting a notable enhan

184 the Tobacco Craving Questionnaire (TCQ) and visual analogue scales (VAS).

185 and medication score (SMS) assessed by daily visual analogue scales (VAS).

186 inuous speech categorization task called the Visual Analogue Scaling (VAS) task.

187 the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air((R)) , a

188 bility to communicate pain (measured using a visual analogue scale [VAS]) and length of ICU stay.

189 comparator; the outcome was pain intensity (Visual analogue scale [VAS]) and physical function (West

190 scale), eye dryness score (EDS) >/=40 (0-100 visual analogue scale [VAS]), and history of artificial

191 nterest are the range of motion (ROM), pain (visual analogue scale, VAS), and circumference of the lo

192 tcomes included nasal-ocular symptom scores (visual analogue scale, VAS), reliever medication use and

193 The 10-point visual analogue scale (VAS10) was used to define the sev

194 Dichotomous questions and visual analogue scales (VASs) were used to assess self-r

195 generic health status assessed by the EQ-5D visual analogue scale was 65.9 (standard deviation = 20.

196 The visual analogue scale was used to assess pain scores bef

197 line, and at 3 and 6 months posttreatment. A visual analogue scale was used to evaluate postoperative

198 A Visual Analogue Scale was used to provide a quantitative

199 em (COMPASS); however, alertness (Bond-Lader Visual Analogue Scales) was better maintained during cog

200 te (M) and whole-body thermal sensation on a visual analogue scale (WBTS) ranging from 0 mm (very col

201 Visual analogue scales were used to assess hunger weekly

202 Visual analogue scales were used to assess indexes of sa

203 Visual analogue scales were used to assess subjects' hun

204 ity Cardiomyopathy Questionnaire and EuroQol visual analogue scale) were evaluated using multivariabl

205 comes included quality of life rated using a visual analogue scale (where 0 represents "worst health"

206 eing (a mean decrease of 1.38 mm on a 100-mm visual-analogue scale), whereas the natalizumab groups r

207 articipation), pain (assessed on an 11-point visual-analogue scale, with higher scores indicating mor

208 pain from these ulcers (measured on a 100-mm visual-analogue scale, with higher scores indicating wor